0.324
전일 마감가:
$0.317
열려 있는:
$0.3165
하루 거래량:
3.78M
Relative Volume:
0.15
시가총액:
$16.52M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.1281
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
-8.16%
1개월 성능:
+4.89%
6개월 성능:
-72.78%
1년 성능:
-82.86%
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PSTV
Plus Therapeutics Inc
|
0.324 | 17.99M | 0 | -12.89M | -11.95M | -2.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-17 | 개시 | D. Boral Capital | Buy |
2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq
Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire
Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus
Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq
Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan
Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa
Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus
Plus Therapeutics stock price target lowered to $3 at H.C. Wainwright - Investing.com India
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus
Plus Therapeutics Soars 122.46% on FDA Clearance for Pediatric Brain Cancer Trial - AInvest
Plus Therapeutics (PSTV) Restructures $15M Equity Financing to Minimize Dilution | PSTV Stock News - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus (PSTV) Upgraded to Buy: Here's Why - Yahoo Finance
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss - AInvest
Why Did Plus Therapeutics (PSTV) Soar 36.24% Pre-Market After Earnings Miss? - AInvest
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):